Deltex Medical Group PLC Director Dealing (7723Z)
September 22 2020 - 10:03AM
UK Regulatory
TIDMDEMG
RNS Number : 7723Z
Deltex Medical Group PLC
22 September 2020
22 September 2020
Deltex Medical Group plc
("Deltex Medical" or the "Company")
Director Dealing
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring
("ODM"), announces that David Moorhouse, Finance Director of the Company, today purchased
370,000 ordinary shares in the Company ("Ordinary Shares") at a price of 1.35 pence per Ordinary
Share and now holds a total of 829,834 Ordinary Shares.
For further information, please contact:-
Deltex Medical Group plc 01243 774 837
Andy Mears, CEO investorinfo@deltexmedical.com
David Moorhouse, Group Finance Director
Nominated Adviser & Broker
Arden Partners plc 020 7614 5900
Ciaran Walsh
Dan Gee-Summons
Joint Broker
Turner Pope Investments (TPI) Ltd 0203 657 0050
Andy Thacker info@turnerpope.com
Zoe Alexander
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies which are primarily
used in critical care and general surgical procedures. Deltex Medical's proprietary oesophageal
Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity in the central circulation
in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates
a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures
such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic
space to have built a robust and credible evidence base demonstrating both the clinical and
economic benefits of its core technology: TrueVue Doppler. This technology has been proven
in a wide range of clinical trials to reduce complications suffered by patients after surgery
and consequently can save hospitals money.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians
with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely
non-invasive monitoring technology which transmits low magnitude, high frequency electrical
signals through the thorax and measures the changes to this signal when the heart pumps blood.
TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information
on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically
stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as a vital part of the anaesthesia
protocols for surgical patients, as well as treating ventilated intensive care patients, including
ventilated COVID-19 patients. Consequently, the Group's focus is on maximising value from
the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical
practice around the world. The Group aims to provide clinicians with a single platform - a
'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated
to be deployed according to the patient's clinical condition as well as the skill and expertise
of the user. Doing this will enable the Group to partner with healthcare providers to support
modern haemodynamic management across the whole hospital.
The Group is currently in the implementation phase of achieving this goal in a number of territories
worldwide, operating directly in the UK and the USA, and via agreements with approximately
40 distributors overseas.
Note: This announcement contains inside information for the purposes of Article 7 of Regulation
(EU) No 596/2014.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
("PDMRs") and persons closely associated with them.1 Details of the persons discharging managerial responsibilities
/ person closely associated
a) Names David Moorhouse - Finance Director
2 Reason for the notification
a) Position/status See 1(a) above for position - classified as
a PDMR of Deltex Medical
b) Initial notification Initial
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Deltex Medical Group plc
b) LEI 213800XN34P6LI8J6M39
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the
financial instrument,
type of instrument Ordinary shares of 1 penny each ("Ordinary
Shares")
b) Identification code GB0059337583
c) Nature of the transaction
Purchase of Ordinary Shares
d) Price(s) and volume(s) Prices(s) Volume(s)
1.35 pence 370,000
d) Aggregated information
- Aggregated volume
- Price N/a
N/a
e) Date of the transaction 22 September 2020
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFIEAIIFFII
(END) Dow Jones Newswires
September 22, 2020 11:03 ET (15:03 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2023 to Apr 2024